Mesoblast Limited (ASX:MSB) Head, Business Development and Licensing, David Oxley, discusses the company’s Phase 3 trials, its agreement with Tasly China and the near-term potential of stem cell medicines.
Most Popular
Britain’s Lloyds criticized for mistreating victims of major fraud
LONDON (Reuters) - Lloyds Banking Group (LLOY.L) has been heavily criticized for mishandling a compensation scheme for victims of one of Britain’s biggest...
AutoZone, HD Supply, Stitch Fix, Chewy & more
Check out the companies making headlines before the bell:AutoZone (AZO) – The auto parts retailer earned $14.30 per share for its first quarter,...
Medical Implant Market to 2022 – Global Analysis and Forecasts by Types, Technologies, Applications...
WiseGuyReports.Com Publish a New Market Research Report On –“ Medical Implant Market to 2022 – Global Analysis and Forecasts by Types, Technologies, Applications...
Why Lockheed Martin gets billions of taxpayer money each year
Lockheed Martin is the top-grossing defense firm in the world and the U.S. government supports that business to the tune of more than...
BlackRock Investment Institute ‘modestly positive’ on risk assets for 2020
FILE PHOTO: A sign for BlackRock Inc hangs above their building in New York U.S., July 16, 2018. REUTERS/Lucas Jackson/File PhotoLONDON (Reuters) -...